186 related articles for article (PubMed ID: 23566774)
1. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
DeSantis SM; Bandyopadhyay D; Baker NL; Randall PK; Anton RF; Prisciandaro JJ
Drug Alcohol Depend; 2013 Sep; 132(1-2):244-50. PubMed ID: 23566774
[TBL] [Abstract][Full Text] [Related]
2. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
3. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
4. Relationship between medication adherence and treatment outcomes: the COMBINE study.
Zweben A; Pettinati HM; Weiss RD; Youngblood M; Cox CE; Mattson ME; Gorroochurn P; Ciraulo D
Alcohol Clin Exp Res; 2008 Sep; 32(9):1661-9. PubMed ID: 18616687
[TBL] [Abstract][Full Text] [Related]
5. The effects of drinking goal on treatment outcome for alcoholism.
Bujarski S; O'Malley SS; Lunny K; Ray LA
J Consult Clin Psychol; 2013 Feb; 81(1):13-22. PubMed ID: 23231573
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Drug Alcohol Depend; 2010 Mar; 107(2-3):221-9. PubMed ID: 19969427
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
8. Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Doggrell SA
Expert Opin Pharmacother; 2006 Oct; 7(15):2169-73. PubMed ID: 17020440
[TBL] [Abstract][Full Text] [Related]
9. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.
Donovan DM; Anton RF; Miller WR; Longabaugh R; Hosking JD; Youngblood M;
J Stud Alcohol Drugs; 2008 Jan; 69(1):5-13. PubMed ID: 18080059
[TBL] [Abstract][Full Text] [Related]
10. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Alcohol; 2012 Mar; 46(2):121-31. PubMed ID: 21925828
[TBL] [Abstract][Full Text] [Related]
11. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Alcohol Clin Exp Res; 2011 Mar; 35(3):523-31. PubMed ID: 21143249
[TBL] [Abstract][Full Text] [Related]
12. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
13. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Weiss RD; O'malley SS; Hosking JD; Locastro JS; Swift R;
J Stud Alcohol Drugs; 2008 Nov; 69(6):878-84. PubMed ID: 18925346
[TBL] [Abstract][Full Text] [Related]
14. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
Gueorguieva R; Wu R; Krystal JH; Donovan D; O'Malley SS
Addict Behav; 2013 May; 38(5):2119-27. PubMed ID: 23435273
[TBL] [Abstract][Full Text] [Related]
15. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
16. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
17. Self-efficacy change as a mediator of associations between therapeutic bond and one-year outcomes in treatments for alcohol dependence.
Hartzler B; Witkiewitz K; Villarroel N; Donovan D
Psychol Addict Behav; 2011 Jun; 25(2):269-78. PubMed ID: 21443293
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
[TBL] [Abstract][Full Text] [Related]
19. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
20. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Falk D; Wang XQ; Liu L; Fertig J; Mattson M; Ryan M; Johnson B; Stout R; Litten RZ
Alcohol Clin Exp Res; 2010 Dec; 34(12):2022-34. PubMed ID: 20659066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
